Respicardia reels in $6M for heart failure/apnea implantable device

Minnesota startup Respicardia secured $6 million in debt financing to advance clinical trial work for a unique implantable device. As the Minneapolis/St. Paul Business Journal reports, the treatment is targeted toward heart failure patients who also experience central sleep apnea, where patients stop breathing briefly through the night. Ares Capital supplied the funding. Story (sub. req.)

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.